GLP-1 & Semaglutide: What Your Doctor Probably Never Told You

If you've heard about semaglutide — sold under names like Ozempic and Wegovy — you've probably also heard the hype. Celebrities crediting it for dramatic weight loss. Social media before-and-afters. Waiting lists at clinics across the country. But between the headlines and the hype, there's a lot that most patients never actually get explained to them. As a physician, I want to change that.

GLP-1 medications are genuinely the most significant advance in obesity medicine in decades. They work. The clinical trial data is impressive. But they're also misunderstood, frequently misused, and often prescribed without the medical oversight that makes the difference between short-term results and long-term transformation. This article is my attempt to give you the full picture.

What is GLP-1, and why does it matter?

GLP-1 stands for glucagon-like peptide-1 — a hormone your gut naturally produces after you eat. It does several important things: it signals to your pancreas to release insulin, it slows how quickly your stomach empties, and critically, it tells your brain that you're full. In people with obesity, this satiety signaling is often blunted — meaning the "I'm satisfied" message either arrives late or never arrives at all.

GLP-1 receptor agonists like semaglutide work by mimicking and amplifying this hormone. The result is a profound reduction in appetite, slower gastric emptying, and — in most patients — a significant drop in caloric intake without the white-knuckle willpower battle that defines most diets. This is not willpower. This is pharmacology correcting a physiological deficit.

What the clinical data actually shows

The STEP trials — the landmark semaglutide clinical program — produced results that genuinely surprised the medical community. Here's what the data shows:

That last number deserves emphasis. The SELECT trial — published in the New England Journal of Medicine in 2023 — showed that semaglutide reduced heart attacks, strokes, and cardiovascular death by 20% in overweight patients with existing cardiovascular disease. We're not just talking about a number on the scale. We're talking about a medication that extends life.

Semaglutide vs. tirzepatide — what's the difference?

Semaglutide (Ozempic, Wegovy) is a GLP-1 receptor agonist. Tirzepatide (Mounjaro, Zepbound) is a dual GIP/GLP-1 receptor agonist — meaning it activates two hormonal pathways simultaneously. In head-to-head data and clinical practice, tirzepatide tends to produce greater weight loss — the SURMOUNT trials showed average losses of 20–22% of total body weight, compared to 15–17% for semaglutide.

Neither is universally better. The right choice depends on your metabolic profile, your insurance or cash-pay situation, and how your body responds. This is a medical decision — not a one-size-fits-all protocol.

What most weight loss clinics get wrong

Here's the uncomfortable truth: the explosion of GLP-1 prescribing has created a lot of bad medical care. Telehealth platforms are prescribing semaglutide after a five-minute questionnaire. Med spas are injecting compounded versions of unknown quality. Patients are losing weight — and also losing muscle mass, experiencing severe GI side effects, and regaining everything when they stop because no one addressed the lifestyle infrastructure underneath.

Physician-supervised GLP-1 treatment is different in several critical ways:

• Baseline metabolic workup. Before prescribing anything, I want to know your fasting insulin, HbA1c, lipid panel, liver function, thyroid, and body composition. The medication doesn't exist in a vacuum.
• Muscle preservation protocol. GLP-1 medications cause loss of both fat and lean muscle mass. Without a structured resistance training protocol and adequate protein intake (≥1.2g per kg of body weight daily), you lose the wrong weight. A good program addresses this from day one.
• Titration management. Starting too fast causes severe nausea and often leads patients to quit. Starting too slow delays results. Proper titration — adjusting dose based on your individual response — is a clinical skill, not a checklist.
• Monitoring for side effects. Rare but serious risks — including pancreatitis, gallbladder disease, and in patients with certain thyroid conditions, contraindications to use — require physician-level judgment to identify and manage.
• Planning for discontinuation. Most patients will eventually taper off GLP-1 medications. Without a metabolic foundation built during treatment, weight regain is almost certain. Building that foundation is the job of medicine.

Who is a good candidate?

GLP-1 medications are FDA-approved for adults with a BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (type 2 diabetes, hypertension, high cholesterol, or obstructive sleep apnea). In practice, I evaluate candidacy based on the full clinical picture — metabolic labs, cardiovascular risk, personal and family history, and goals.

There are also contraindications. Patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 should not take GLP-1 agonists. Patients with a history of pancreatitis require careful evaluation. This is why a physician — not an algorithm — needs to be involved.

What results look like with proper oversight

In a well-run physician-supervised GLP-1 program, here's what the trajectory typically looks like:

• Month 1: 1–3% total body weight loss. Appetite noticeably reduced. GI side effects managed with slow titration.
• Month 3: 5–8% total body weight loss. Metabolic labs beginning to improve — glucose, triglycerides, blood pressure. Maintenance dose reached or approaching.
• Month 6: 10–15% total body weight loss. Body composition shift — fat loss with muscle preservation if resistance training protocol followed. Significant improvement in metabolic markers.
• Month 12: 15–22% total body weight loss (tirzepatide). Metabolic disease remission in many patients. Transition to maintenance planning begins.

These are clinical trial numbers — real-world results with proper oversight. What I see without oversight: faster initial weight loss, followed by plateau, muscle loss, GI intolerance, and eventual discontinuation with rebound.

The bottom line

GLP-1 medications represent a genuine medical breakthrough. Used correctly — under physician supervision, with appropriate baseline evaluation, a muscle-preservation protocol, and a plan for the long term — they can produce metabolic transformations that were essentially impossible with lifestyle alone. Used incorrectly, they're an expensive, temporary fix that leaves patients worse off than before.

If you're considering a GLP-1 medication, the most important question to ask is not "which one should I take" — it's "who is going to manage this with me." The medication is a tool. The physician is the craftsman.